Press "Enter" to skip to content

USFDA issues 5 observations to Dr Reddy’s plant in Hyderabad

"The audit of our active pharmaceutical ingredient (API) manufacturing plant 2 at Bollaram, Hyderabad by the United States Food and Drug Administration (USFDA), has been completed today," Dr Reddy’s said in a filing to BSE.

Original source: https://health.economictimes.indiatimes.com/news/pharma/usfda-issues-5-observations-to-dr-reddys-plant-in-hyderabad/70193988?utm_source=RSS&utm_medium=ETRSS

Also Read:   Clinic waiting room in Harlem becomes experiment in humanizing medicine